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Abstract 
Vibrational spectroscopy is currently widely explored as a tool in biomedical applications. An 
area at the forefront of this field is the use of vibrational spectroscopy for disease diagnosis, 
ultimately aiming towards spectral pathology. However, while this field shows promising 
results, moving this technique into the clinic faces the challenges of widespread clinical trials 
and legislative approval. While spectral pathology has received a lot of attention, there are 
many other biomedical applications of vibrational spectroscopy, which could potentially be 
translated to applications with greater ease. A particularly promising application is the use of 
vibrational spectroscopic techniques to study the interaction of drugs with cells. Many 
studies have demonstrated the ability to detect biochemical changes in cells in response to 
drug application, using both infrared and Raman spectroscopy.  This has shown potential for 
use in high throughput screening (HTS) applications, for screening of efficacy and mode of 
action of potential drug candidates, to speed up the drug discovery process. HTS is still a 
relatively new and growing area of research and, therefore, there is more potential for new 
techniques to move into and shape this field. Vibrational spectroscopic techniques come with 
many benefits over the techniques used currently in HTS, primarily based on fluorescence 
assays to detect specific binding interactions or phenotypes. They are label free, and an 
infrared or Raman spectrum provides a wealth of biochemical information, and therefore 
could reveal not only information about a specific interaction, but about how the overall 
biochemistry of a cell changes in response to application of a drug candidate. Therefore, drug 
mode of action could be elucidated. This review will investigate the potential for vibrational 
spectroscopy, particularly FTIR and Raman spectroscopy, to benefit the field of HTS and 
improve the drug development process. In addition to FTIR and Raman spectroscopy, surface 
enhanced Raman spectroscopy (SERS), coherent anti-Stokes Raman spectroscopy (CARS) and 
stimulated Raman spectroscopy (SRS), will be investigated as an alternative tool in the HTS 
process. 
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1. Introduction 
 
Vibrational spectroscopy has gained momentum as an important tool for biomedical 
applications. Vibrational spectroscopy encompasses several techniques, most significantly, 
infrared (IR) spectroscopy and Raman spectroscopy, which detect bond vibrations. These 
techniques have been applied to biological samples, including tissue in vivo[1], excised tissue 
ex vivo, tissue sections ex vivo[2], blood[3] and serum[4] ex vivo, and single cells[5] in vitro, in 
which signals from biomolecules such as proteins, lipids and DNA/RNA are observed and 
used to characterise samples.[6] In particular, the application of IR and Raman spectroscopy 
for label free disease diagnosis is being extensively studied in the biomedical vibrational 
spectroscopy field. Extensive research has been invested into the potential for increased 
objectivity and automation in histopathology and cytology with a movement towards 
spectral pathology as the ultimate goal.[6] Standard clinical practice requires analysis of 
haematoxylin & eosin (H&E) stained tissue sections by a pathologist for disease diagnosis. 
Attempts are being made to move towards more automated disease diagnosis in tissue 
sections, and cytology samples, using vibrational spectroscopy. One of the major advantages 
of IR and Raman spectroscopy over, for example, histology, fluorescence staining and 
immunohistochemistry, is that it is a label free method, detecting native biochemical markers 
of cells and tissue via characteristic bond vibrations, and associating changes in them with 
disease onset and progression, rather than the morphological changes which characterise the 
disease.[6]  
 
In 2014, the Clinical Infrared and Raman Spectroscopy for Medical Diagnosis (CLIRSPEC) 
Network, funded by UK EPSRC, was set up with the goal of accelerating the translation of 
spectroscopy into the clinic.[7] Raman4Clinics is a similar European network (EU Cost Action 
BM1401), specifically established to promote the translation of Raman spectroscopy into 
clinical applications.[8] Raman spectroscopy has already been applied for clinical use in vivo, 
with a particularly exciting recent development, in which Raman spectroscopy was used in 
real time for assessment of tumour margins for determining tissue to be excised in a brain 
tumour operation, being featured on the BBC news.[9,10] IR spectroscopy is also moving 
towards clinical applications, a particularly exciting clinical trial is currently active in 
Thailand, demonstrating the use of attenuated total refection Fourier transform IR (ATR-
FTIR) spectroscopy for detection of malaria in blood samples using minimal sample 
preparation, allowing for quick and easy detection with portable devices and no need for 
scientist input.[3,11] 
 
While there is an intensive drive towards moving vibrational spectroscopy techniques into 
the clinic for diagnostic purpose, there is also huge scope for the use of vibrational 
spectroscopy in other biomedical research areas. There are many challenges facing translating 
vibrational applications into the clinic. These include the extensive ethical considerations and 
approval required for in vivo and ex vivo use, and the resistance to change among pathologists 
who have been following the same established protocols for an extensive time.[6] Another 
area where there is potential for the use of vibrational spectroscopy for biomedical 
application is as a tool in drug development; pre-clinical screening drug candidates to select 
successful ‘hits’ to take forward into clinical trials. As this generally involves in vitro models 
and is itself a more recent and growing area of development, there is potential to have a 
larger impact in shaping the research within this field. There is huge legislative pressure on 
the development of in vitro methods to replace animal testing, making in vitro based drug 
testing platforms of significant importance (Directive 2010/63/EU on the protection of animals 
used for scientific purposes[12]; United States the 106th Congress – Public Law 106 – 545 – Dec 
19, 2000[13]). Currently, high throughput screening (HTS) methods for detecting successful 
lead drug candidates are highly dependent on fluorescence techniques for assessment of 
efficacy.[14] The assays used tend to probe specific binding interactions between a drug and 
protein, reporting in a univariate manner via fluorescence. These techniques require assays to 
be available for each specific interaction or phenotype; probing just one interaction and not 
the additional effects a drug may have. The cellular samples may also be subject to labeling or 
photobleaching and are destructive techniques as a result.  
 
Both IR and Raman spectroscopy have been used to assess the effects of drugs on cells, with 
potential to measure changes in a high throughput manner and therefore be used in drug 
screening.[15,16] These techniques could provide advantages over standard high throughput 
fluorescence based methods by revealing increased biochemical information using a label free 
method. They detect detailed biochemical information in a more quantitative manner, with 
the potential to not only pick up a change in response to drug treatment, but to reveal 
detailed biochemical information on how drugs may alter cellular biochemistry and reveal a 
potential ‘mode of action’.[17]  
 
In addition to traditional IR and Raman spectroscopic methods, there are more advanced 
vibrational techniques that can be employed for alternative high throughput screening 
assays. Surface enhanced Raman spectroscopy (SERS), has been used to develop assays for 
various applications with many benefits over fluorescent assays.[18] These include lack of 
photobleaching, ability to multiplex and probe multiple interactions in one assay, and 
increased ability for quantification of measurements. SERS can also be used as a means of 
simply enhancing Raman signals, considerably reducing acquisition times in Raman 
analysis.[19] Coherent anti-Stokes Raman spectroscopy (CARS) and stimulated Raman 
spectroscopy (SRS) may lead the future for spectroscopic HTS. They are nonlinear Raman 
techniques, which overcome the inherent weakness of spontaneous Raman spectroscopy.[20] 
Therefore, measurements can be performed faster, a vital benefit for HTS. 
 
This review will therefore focus on the potential of vibrational spectroscopy for use in 
analysing the interaction of drugs with cells and, in particular, how these techniques could 
potentially be employed for the screening of drug candidates in a high throughput manner, a 
label free method providing a wealth of biochemical information that could reveal important 
information regarding the interaction of drug candidates with cells. Ultimately these HTS 
techniques could be used for companion diagnostics and personalised medicine, assessing 
suitability of a particular therapy for a particular patient or patient group.  
 
2. Current high throughput screening techniques: could vibrational spectroscopic 
screening improve these? 
 
High throughput screening (HTS) is widely used in the pharmaceutical industry for faster 
identification of drug ‘hits’, compounds exhibiting a desired biological response to a potential 
drug compound.[21] Often, this biological response involves a binding event between a 
compound and a particular protein target or DNA[22], and this is typically monitored using a 
fluorescence assay based technique. HTS aids drug discovery by speeding up the process of 
identifying compounds, from large compound libraries, with the desired mode of action. 
Development of a new drug product from start to end is a very long process, taking on 
average 12 years, and costing, on average $1.2 billion per product.[23] Moving from low 
throughput techniques at the initial stages of drug development, whereby compounds are 
screened one at a time in a highly manual intensive manner, to highly automated high 
throughput screening techniques allowing multiple compounds to be screened 
simultaneously, can help minimise the time for the drug development process. To compare, 
HTS allows ca. 10,000 compounds, and even up to 100,000 compounds, to be screened in one 
day, compared to a maximum of ca. 500 compounds using low throughput screening 
techniques.[21] Initial compound screening generally identifies compounds that exhibit the 
desired activity. For successful compounds, modified versions can then be developed using 
synthetic techniques, producing new libraries of compounds to be screened. It is also 
necessary to consider optimal concentration of ‘hit’ compounds, any negative side effects 
they may have and their toxicity. Therefore, it is appropriate to employ screening techniques 
at various stages in the drug discovery process. HTS allows many more compounds to be 
screened in one day, and could easily reduce a process that could take 1 year to screen using 
low throughput methods, to only 1 day using HTS.  
 
The key characteristics of HTS techniques are: simple, fast, cheap and efficient. Compounds 
are typically screened in 96-, 384- or 1536- well plates, ideally using minimal volumes.[14] 
The most recent developments using microfluidics have allowed even smaller volumes to be 
used with increased throughput capability.[24] In order to understand the potential benefits 
of vibrational spectroscopic techniques in HTS, over current techniques, it is important to 
understand the principle behind current techniques along with their limitations.  
 
Vibrational spectroscopic screening is being considered as an alternative and improved 
technique in screening potential drug compounds for efficacy; potentially in conjunction with 
other factors such as mode of action and toxicity in a high throughput manner. Primarily, this 
review will focus on in vitro cell based assays for compound screening. In HTS this is one of 
the two main assay types (the other being biochemical assays). In a biochemical assay, 
compounds are screened for action on their particular target in their purified form.[14] 
Biochemical assays can be heterogeneous or homogenous, heterogeneous assays requiring 
multiple steps, compared to simpler homogeneous assays that are simply ‘mix and read’ type 
systems. Detection techniques in HTS are predominantly fluorescence and luminescence 
based techniques, including standard fluorescence and luminescence assays as well as 
extensions of these such as fluorescence resonance energy transfer (FRET)[25], fluorescence 
polarization (FP)[26], homogeneous time resolved fluorescence (HTRF)[27] and fluorescence 
correlation spectroscopy (FCS)[28]. Assays are developed to detect specific binding processes 
or to probe particular pathways, networks or phenotypes.[29] Some of the most common 
targets are G-protein coupled receptors, enzymes, hormones, ion-channels, nuclear receptors 
and DNA.[14] Both fluorescence and luminescence detect photons, with some common 
assays using luciferase reporters[30], green fluorescent proteins[31], β-galactoside[32] and β-
lactamase[33].[29] Common fluorescent reagents for cytotoxicity screening are Alamar 
blue[34], MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)[34] and 
sulforhodamine B[35].  
 
To answer the question ‘could high throughput vibrational spectroscopic screening improve 
drug development?’, it is necessary to consider whether it can meet the basic needs of HTS by 
being simple, fast, cheap and efficient, and, ultimately, whether it can supersede the current 
techniques in doing so. Standard HTS assays often monitor only one interaction, giving a ‘on’ 
or ‘off’ response typically in reaction to a binding event, at best giving a graded readout, 
which would provide quantitative information also on this single response. Vibrational 
spectroscopy can provide an ‘on’ or ‘off’ response also, in terms of overall changes in the 
spectrum in response to drug application, but could also be used to reveal a whole array of 
additional information; how a drug interacts with a cell, possible toxic side effects of the 
drug, how a drug effects the biochemical make up of a cell in terms of e.g. protein/lipid/DNA 
concentration. This may spare the need for additional assays, increasing speed. In addition, 
another benefit is the label-free aspect of the vibrational techniques, which both decreases 
additional cost for fluorescent reagents, and makes the assay process simpler, faster and more 
efficient by decreasing additional steps involved in adding reagents for detection. While the 
addition of spectroscopic instruments may increase cost of screening, high throughput 
spectrometers are already on the market and costs will decrease as these become more 
popular.[36]  
 
While the focus is on detection of drug interaction in cell-based assays via vibrational 
spectroscopy, there is also potential for applications in biochemical assays with isolated cell 
components. In particular, the technique of surface enhanced Raman spectroscopy (SERS) has 
been used extensively in assay development in other biomedical research areas for many 
applications, including ELISA type immunoassays.[37] It has many benefits over standard 
fluorescence based assays, including lack of photobleaching, multiplexing ability[38] and 
often increased sensitivity. SERS has also been applied to in vitro cellular assays, to analyse, 
for example, enzyme activity.[18] Therefore, while SERS does not have the label-free 
advantage of native vibrational spectroscopic techniques, it provides many benefits over 
traditional fluorescence techniques with potential to increase speed through, for example, 
multiplexing capabilities. 
 
3. Data analysis: interpreting spectroscopic data 
 
One of the major benefits of vibrational spectroscopy over fluorescence is the wealth of 
information that can be obtained. An individual spectrum acquired using IR or Raman 
spectroscopy contains the signatures of the many constituent biomolecules, over many data 
points, and therefore data analysis is carried out in a multivariate manner, to elucidate the 
wealth of information on how a specific drug candidate affects a cell. However, with this 
comes the requirement for more complicated data analysis protocols.  
 
In this section, some of the major considerations to be made for interpretation of 
spectroscopic data in terms of pre-processing and post-processing analysis techniques will be 
explored. Byrne et al.[39] recently summarised the major pre and post processing methods 
employed for IR and Raman spectroscopic analysis of tissues and cells. Pre processing 
methods involve improving spectral quality by removal of background features caused by 
physical effects, sample preparation and substrate. This helps remove the effects of 
instrument-to-instrument and sample-to-sample variation, therefore standardising the 
technique for translation into clinical and HTS applications. Particular pre processing 
considerations for IR spectroscopy involve applying Mie scattering correction algorithms[40] 
and water correction algorithms[41] for aqueous samples (see section 4 for a full discussion). 
A major consideration for both IR and Raman spectroscopy is substrate, with different 
substrates creating different background contributions in the spectra.[42] Due to difficulties 
removing all background contributions experimentally, algorithms, going from simple 
straight or polynomial line subtractions to more complicated algorithms, such as extended 
multiplicative scatter correction (EMSC)[43] and the “rubber band” model, are often applied 
to spectra before further data processing. Additional commonly employed pre processing 
steps include smoothing, truncation, normalization, taking spectral derivatives and cosmic 
ray removal (Raman).[44]  
 
Moving to post processing methods, the large volume of information obtained from 
vibrational spectroscopy, requires multivariate data analysis to extract information, in this 
case regarding how a drug interacts with and alters a cell. In fluorescence spectroscopy, 
typically only one parameter is measured, i.e. fluorescence at a specific wavelength. Most 
fluorescence based techniques work via a simple ‘on/off’ mechanism whereby fluorescence is 
switched ‘on’ or ‘off’ in response to the biological event being probed. At best, this can extend 
to a univariate model, giving quantitative information by measuring the absolute 
fluorescence, and comparing it to calibration data. In comparison, a single IR or Raman 
spectrum can have hundreds or thousands of data points, recording multiple wavelengths in 
one spectrum, revealing detailed quantitative information regarding subtle changes in 
cellular biochemistry.  Signals corresponding to particular bond vibrations are observed in 
spectra and each reports somewhat quantitatively via signal intensity on biochemical 
composition. This can reveal detailed metabolic information. Therefore, subtle changes in 
metabolism in cells can potentially be picked up using vibrational spectroscopic techniques, 
and the mass of information available in a single spectrum allows potential ‘mode of action’ 
to be determined, in addition to efficacy. It is possible to consider only one or two specific 
wavenumbers when analysing this data, therefore simplifying to univariate or bivariate data. 
However, this fails to consider the volume of additional information that could provide 
additional discriminatory power. Therefore, multivariate models have been developed to 
consider the large number of parameters contained within a hyperdimensional dataset. 
 
While multivariate analysis can provide additional discriminatory power, these require more 
complex data processing that may take a longer time and require more expensive software. 
Recent developments in IR spectroscopy have looked at discrete frequency imaging using, for 
example, quantum cascade lasers (QCL)[45], where spectra are acquired over only small 
wavenumber ranges. These techniques have the advantage of speed, if it is possible to 
discriminate between conditions using a narrower spectral range than standard range of FTIR 
spectroscopy. Some of the most common multivariate models are principle component 
analysis (PCA) and partial least squares regression analysis (PLSR), which look for the largest 
variances in the data set in an unsupervised and supervised manner respectively. Cluster 
analysis is, perhaps, the simplest multivariate analysis technique. It groups spectra according 
to similarity, with similar spectra being put in one ‘cluster’. For drug-cell studies hierarchical 
cluster analysis[46] is the most widely applied cluster analysis method.  
 
PCA is the most widely used data analysis technique in this area of research. It is used to 
reduce the data dimensionality by creating new variables, principle components, to describe 
the maximum variance in the data set. Principle component one will describe the maximum 
variance followed by principle component two for the next most variance, and so on. This 
technique can, for example, distinguish between two sets of conditions such as with and 
without drug, and the principle component loadings will show the major variances in 
spectral features that differ between conditions.[47] By assigning these differences to 
particular biomolecule vibrations, insight can be gained into how and where a drug is 
interacting with cells. Another commonly used data analysis technique is PLSR. PLSR could 
have important application, in particular, to the study of cells using vibrational spectroscopy, 
as it is used to build up a predictive model on how spectral signature changes in response to 
a systematic change in conditions. Nawaz et al.[48] performed a particularly interesting study 
where they highlighted the ability of PLSR to distinguish changes in spectral signals resulting 
from chemical binding of the drug cisplatin to DNA, and the subsequent physiological 
changes this induced. By building up a database of spectral responses from drugs of known 
mechanism, this could serve as a reference for inferring ‘mode of action’ for new drugs 
during HTS screening application. Therefore, PLSR could prove to be a powerful technique 
for HTS application. In addition to cluster analysis, PCA and PLSR, there are numerous other 
data analysis techniques being employed in the field of biomedical spectroscopy. These 
include vertex component analysis[49], classic least squares analysis[50], spectral cross 
correlation analysis[50], artificial neural networks[51] and genetic algorithm[52], but for the 
purpose of this review these will not be discussed further. For further discussion of these 
techniques and their application, reference is made to Byrne et al.[39]. 
 
It is worth noting also that while vibrational spectroscopy reveals a wealth of information in 
one spectrum, it can only really be considered semi-quantitative. This is a result of 
macromolecular bond vibration overlap in spectra due to the large volume of signals from 
and therefore peaks tend to have contributions from a number of species.[53] Therefore, 
while analysis of changing intensity of individual bands could provide quantitative 
information regarding subtle changes in biochemical composition, care must be taken as 
often peaks have underlying contributions from other species contributing to absolute 
intensity. 
 
To conclude this section, fluorescence assays are standardly developed to monitor one 
specific drug-protein interaction targeted by the drug. While vibrational spectroscopic 
techniques could potentially monitor spectral changes in response to such a drug-protein 
interaction, more detailed information can be gained, potentially revealing additional 
interactions that a particular drug may have on the metabolism of the cell. Therefore, there is 
potential for a very detailed picture of drug-cell interaction to be gained through vibrational 
spectroscopic analysis. One ‘assay’ using vibrational spectroscopy could potentially be used 
to screen drugs with multiple and different modes of action in one step. Using fluorescence 
this would require multiple screening steps with different assays to report on each potential 
interaction, and would depend upon having a good knowledge of the potential interactions, 
and an assay available to probe that. While drugs are commonly designed with a particular 
drug-protein interaction in mind, opening up the possibility of screening for multiple ‘modes 
of action’ could provide many benefits. Detailed biochemical information is gained, and this 
could also screen for efficacy and toxicity simultaneously. In order to provide this detailed 
information on drug-cell interaction, however, vibrational spectra must first be subjected to 
pre and post processing data analysis to extract the subtle changes in biochemistry using 
multivariate techniques. 
 
4. Infrared spectroscopy for monitoring drug-cell interaction 
 
There has been extensive research using IR spectroscopy, performed in vitro, to monitor the 
cellular response to drugs. Much of this research has focused on cancer cells and monitoring 
the changes in the spectral signatures of cells in response to anticancer agents. In 2015, 
Hughes et al.[15] highlighted, in a short review article, the potential for IR microspectroscopy 
to be used as a label free screening platform – “Preclinical screening of anticancer drugs using 
infrared (IR) microspectroscopy”.  
 
Many studies have reported the effects of anticancer agents, including polyphenols[54], 
cardiotonic steroids[55], and platinum compounds[56,57], on cancer cells using IR 
spectroscopy. Typically, IR spectroscopy uses Fourier transform (FTIR), to allow fast 
acquisition of data over a wide spectral range. There are three primary measuring methods 
used in FTIR spectroscopy – transmission, transflection and attenuated total reflection (ATR). 
It is important to consider the advantages and disadvantages of these techniques in terms of 
speed, cost and sample preparation if techniques are ultimately to be translated to a HTS 
platform. All three methods have been used to investigate drug-cell interactions. The primary 
disadvantage of transmission IR is that it generally requires high cost substrates such as 
calcium fluoride, which are also brittle, and therefore care must be taken when handling 
them.[39] The cost of the substrate would make translating this technique into a HTS 
platform difficult as a result of the cost involved. However, if substrates could be reused this 
would reduce the consumable cost. Transflection IR, in comparison, uses cheap MirrIR slides 
that are easier to handle.[39] As the beam passes through the sample twice, transflection IR 
also results in better signal-to-noise, and a reduced acquisition time can be used to achieve 
the same quality spectra as with transmission IR.[58] Alternatively, this means for 
transflection IR can use samples with less thickness can be used. The major downfall of 
transflection IR, however, is the presence of the “Electric Field Standing Wave” effect, with 
can affect the resulting absorbance profile, making quantitative measurements inaccurate.[58] 
Finally, ATR IR gives the best signal-to-noise, and is therefore the fastest technique.[58] It also 
requires little sample preparation, however varying force applied to the sample can affect the 
signals in the spectra and therefore correction algorithms are often required.[59] The pressure 
applied also has the potential to damage the sample.[58]    
 
Another important consideration in FTIR spectroscopy, is that historically synchrotron 
radiation was commonly used to obtain sufficient signal to noise for high spatial resolution 
imaging. While FTIR spectroscopic studies on biological samples were previously highly 
dependent on synchrotron radiation sources due to diffraction limitations using a globar 
source limiting spatial resolution[60], recent advances have expanded the potential of 
benchtop instruments to achieve desirable resolutions[61]. It also may not be necessary to 
achieve high spatial resolutions for HTS techniques, instead taking spectra from a population 
of cells, representative of the sample. Draux et al.[62] demonstrated that FTIR spectral 
response of Calu-1 lung cancer cells, to the drug gemcitabine, was similar between single cell 
measurements using synchrotron radiation FTIR (SR-FTIR) and cell population 
measurements using a benchtop instrument in transmission mode with a HTS-XT (high 
throughput screening eXTension) attachment. Inhibition of proliferation upon drug treatment 
was detected, provided the growth inhibition was above 25%, and a concentration dependent 
response was observed. In this example, hierarchical cluster analysis was used for data 
analysis, one of the simplest multivariate data analysis techniques.  
 
One of the major downfalls of IR spectroscopy is that water is strongly IR active. Therefore, in 
aqueous biological samples, a lot of information is ‘swamped’ by the strong water vibration 
signals observed at ca. 3300 cm–1, and ca. 1650 cm–1. Notably, the band at ca. 1650 cm–1 appears 
in the region of particular interest for biological samples, overlapping with the protein amide-
I band at ca. 1655 cm–1. This is ultimately a problem when moving towards live cell analysis in 
vitro and many of the cell-drug interaction studies have been carried out on fixed cells. Recent 
developments using microfluidic style devices have allowed for better live cell analysis, and 
could be vital to move this to a HTS platform.[58] Microfluidic devices tend to use minimal 
volumes, which is an added advantage for HTS considerations. Even when the aqueous 
environment of the cells is removed, contributions from water vapor, as well as CO2, in the 
atmosphere can affect spectra.[41] Much of this water and CO2 vapor contribution can be 
removed by purging instruments. It is likely, however, that water contributions will still be 
observed, and water correction algorithms need to be employed to remove these. These 
algorithms could also allow cells in live aqueous environment to be investigated successfully. 
Therefore, this drawback no longer limits the use of IR spectroscopy, but makes data analysis 
protocols more complicated to allow for correction algorithms to be developed and 
employed.  
 
Another major consideration in IR spectroscopy is Mie scattering, a physical scattering effect 
caused by the wavelength of light being close to the size of object being probed, i.e. cells and 
subcellular organelles. In addition to adding a broad, undulating background to the spectra, 
resonant effects can cause significant distortions of the characteristic spectral features. Again, 
correction algorithms have been developed to remove the effects of Mie scattering. However, 
correction algorithms are not perfect and attempts are constantly being made to improve 
these to better correct for Mie scattering.[40] In particular, when considering monitoring 
spectral changes in response to potential drug compounds, it is important that Mie scattering 
contributions are considered. This is particularly relevant in this application, as drugs will 
often cause morphological, as well as chemical changes to cells. Morphological changes will 
potentially lead to changes in Mie scattering contribution and therefore this, and not chemical 
changes, could be the cause of spectral changes. Therefore, it is important to understand and 
eliminate the effects of Mie scattering when considering chemical changes in response to drug 
candidates. There is particular relevance of this effect when considering the cell nucleus, 
which is often the cellular region with most Mie scattering, and is also often subject to 
significant morphological changes in response to drugs that cause apoptosis. Drugs often 
work via induction of apoptosis, which commonly causes nuclear condensation and 
fragmentation, which could have a significant effect on Mie scattering contribution. While 
these contributions complicate IR spectroscopic measurements, it should be noted that they 
also provide additional information regarding the physical characteristics of cells i.e. 
morphology, which could potentially be used in discrimination. For example, this could 
potentially discriminate normal from apoptotic cells due to morphological changes, in 
particular, from the cell nucleus. Therefore, both physical and chemical information could be 
gained from IR spectroscopy, providing that contributions can be deconvoluted successfully, 
providing a wealth of information for spectroscopic discrimination. 
 
Another important point for consideration in IR, and also Raman, spectroscopy, which has 
been addressed in various studies, and which would be applicable to all techniques looking 
at cell-drug interactions, is cell cycle. It is important to consider spectral differences between 
cells at different point in cell cycle, to ensure that spectral responses observed upon drug 
treatment are due to the drug and not cell cycle differences.[63] If IR spectroscopy is capable 
of distinguishing cell cycle in conjunction with response to drug compound, this provides 
information not accessible using simple fluorescent techniques by which cell cycle is not 
monitored. Initial studies into the effect of cell cycle on drug response used complimentary 
fluorescence staining techniques to ascertain and separate cells by cell cycle.[63,64] Hughes et 
al.[63] used the dye propidium iodide (PI), which binds in a quantitative manner to double-
stranded DNA, combined with fluorescence-activated cell sorting (FACS) to separate cells 
into G1 (Gap 1), S/G2 (synthesis/post DNA synthesis) and M (mitosis) phases. In this study, 
the effect of the drug 5-fluorouracil (5FU), known to disrupt S phase, and three novel gold-
based chemotherapeutic compounds (KF0101 (KF1), KF0113 and KF0501), on A-498 renal 
carcinoma cells, was investigated using SR-FTIR. Cells were treated with each 
chemotherapeutic agent for 24 hrs and 72 hrs, and untreated and treated cells were fixed 
before staining with PI and FACS sorting to separate cells into cell cycle phase. Results 
highlighted the significance of separating cells by cell cycle, with discrimination by PCA 
between untreated, 5FU treated and KF1 treated observed for S phase cells but not the full 
dataset. This is consistent with the known action of 5FU. Some of the important 
considerations already highlighted for IR spectroscopy were also highlighted in this study, 
particularly the importance of performing Mie scattering correction. Significant differences in 
Mie scattering contribution between the different cell cycle stages were observed, likely due 
to changes in amount of cellular content[65], and therefore the RMieS-EMSC correction 
algorithm[40] was used. The ability to detect changes after 24 hr treatment was highlighted as 
an advantage with respect to HTS, and the benefit of distinguishing cell cycle without 
additional staining was confirmed as an ideal next step. In addition, this particular study was 
carried out on fixed cells and using a synchrotron radiation source. A similar study was 
carried out by Derenne et al.[64] looking at cell cycle effects on PC-3 prostate cancer cells in 
response to anticancer drugs, using a benchtop instrument. This study looked at the 
difference between G0/G1 and G2/M phase cells both untreated and treated with paclitaxel, an 
anticancer drug that stops microtubule depolymerisation in the M phase of the cell cycle. 
Again this study relied on fluorescence data to assign cell cycle stage, and differences in the 
FTIR spectra between cell cycle stages were investigated. The primary conclusion, however, 
was that the FTIR spectral signatures did not show large variations between cell cycle stage, 
in comparison to the differences observed upon drug treatment.  
 
In a more recent study from Jimenez-Hernandez et al.[66] (Figure 1), a robust support vector 
machine (SVM) was employed to discriminate FTIR spectral signatures for different cell cycle 
stages, previously deemed “small” by Derenne et al.[64], with 83.7% average accuracy. While 
these spectral differences may be small, the ability to discriminate cell cycle stages using 
FTIR, allows more detailed and accurate analysis of drug effects. As well as removing the 
possibility of cell cycle stage differences confounding drug response results, this could 
provide a platform for determining ‘mode of action’ of a drug, through knowledge of what 
cell cycle stage is most affected by the drug. Importantly, this study highlighted that, for 
Caki-2 renal cell carcinoma cells treated with 5FU and paclitaxel for 24 h, the primary FTIR 
spectral signature changes could be attributed to apoptosis. These changes relate to lipid 
changes and reduced protein, previously observed as characteristics of apoptosis observed in 
FTIR spectra.[67,68] While, observation of a distinguishable apoptotic response could still 
prove useful as a marker in HTS technologies, ability to extract more detailed spectroscopic 
information regarding ‘mode of action’ shorter drug exposure time may be required.    
 
It is not only cell cycle stages that could confound FTIR spectral analysis of cells responding 
to drug treatment. Rutter et al.[69] investigated the difference in response of gemcitabine-
sensitive and gemcitabine-resistant CALU-1 epidermoid lung cancer cells to gemcitabine. By 
cloning sensitive and resistant cell populations, from a mixed population, they showed that 
PCA did not discriminate treated from untreated resistant cells, but did for sensitive cells. 
While, obtaining multiple spectra over a cell population growing in, for example, a well in a 
96-well plate, may be enough to average effects such as cell cycle contribution and 
resistance/sensitivity, it would be more accurate to take these characteristics into 
consideration. FTIR spectroscopy has the potential to provide spectral signatures that allow 
these multiple characteristics to be analysed in addition to drug response.  
 
5. Raman spectroscopy for monitoring drug-cell interaction 
 
The potential of IR spectroscopy to monitor drug-cell interactions and potentially translate 
into a HTS platform for drug screening has now been explored extensively. There has been 
similar research into drug-cell interaction using Raman spectroscopy. The main downfall of 
Raman in comparison to IR spectroscopy is low signal intensity, and therefore longer 
acquisition times required to achieve sufficient spectral information. As speed is one of the 
primary characteristics desirable for HTS, this is a significant hurdle for Raman to be 
employed in such a system. However, Raman spectroscopy also exhibits many advantages in 
comparison to IR spectroscopy. The main advantage of Raman spectroscopy is that high 
spatial resolutions in a confocal microscopic geometry are possible due to the use of optical 
wavelengths.[70] It is a scattering technique, allowing any ultraviolet (UV), visible or IR 
wavelength to be used. While UV wavelengths allow higher spatial resolutions and scattering 
efficiencies to be achieved, there is increased susceptibility to photodamage and fluorescence 
from resonant cellular chromophores at these wavelengths. Therefore, near IR (NIR) is often 
the wavelength of choice for Raman spectroscopy to achieve an optimal balance of spatial 
resolution along with limited photodamage and fluorescence background.  
 
In addition, water is only very weakly Raman active, and therefore aqueous samples can be 
analysed easily, without the need for complicated algorithms for water correction. Similarly, 
Mie scattering is not an issue in Raman spectroscopy, again negating the need for complex 
computer algorithms for spectral adjustment. Raman spectroscopy is compatible with 
samples in almost any state, while IR spectroscopy requires specific and more complicated 
sample preparation steps when used in transmission and transflection mode. The one 
particular consideration that must be made in terms of sample preparation for Raman 
spectroscopy, is choice of sample substrate.[42] Plastic and glass both give background 
signals in Raman spectra, meaning that often cell samples are plated on substrates such as 
CaF2, BaF2 or sapphire windows with minimal background.[42] For a HTS platform this is an 
important consideration in terms of cost, as these background free substrates are more 
expensive. Glass can be used as a Raman substrate with minimal background contribution, 
particularly at certain wavelengths. Therefore, while there is less background using the more 
expensive substrates, where cost is important, it is possible to use glass. It is also worth 
considering more intricate substrate platforms, particularly in the context of HTS, such as 
microarrays. Buckmaster et al.[71] report on the use of a gold-patterned silicon oxide 
substrate, for attachment of single-cells, and subsequent Raman analysis. Here, the response 
of single DAOY human medulloblastoma cells to the chemotherapeutic agent etoposide was 
investigated in real time at various time points. Raman spectra revealed detailed biochemical 
information, and were able to detect apoptotic changes in single cells in response to drug 
treatment. This study also found that a small number of cells showed resistance, and 
therefore was able to discriminate varied responses within a cell population, by performing 
single cell analysis on this microarray. The changes in intensity of individual peaks 
corresponding to particular bond vibrations were investigated, and thus considered data in a 
univariate manner. Similar to IR spectroscopy, however, Raman analysis provides a wealth of 
information and therefore multivariate data analysis techniques are often employed for 
spectral analysis. 
 
Raman spectroscopic analysis of drug-cell interactions has focused both on changes in the 
cellular Raman spectra to drug application, and also to intracellular tracking of the drug and 
its metabolites. Therefore, a wealth of information can be gained using Raman spectroscopic 
analysis. Subcellular resolution can be achieved due to the high spatial resolution achievable, 
allowing intracellular organelles to be resolved, often using cluster analysis, an unsupervised 
multivariate data analysis technique. Raman spectra are typically recorded at higher spectral 
resolution than IR spectra, and therefore more detailed biochemical information can be 
gained, with more potential for elucidating ‘modes of action’ by analysis of the detailed 
spectral changes. El-Mashtoly et al.[46] demonstrated the capability of Raman spectroscopy 
for monitoring distribution of erlotinib, and its metabolic products in colorectal 
adenocarcinoma SW480 cells. Insight into the subcellular localisation and metabolic products 
of erlotinib was revealed, hierarchical cluster analysis allowing subcellular resolution in a non 
invasive and label free manner, and allowing intracellular location of erlotinib and its 
metabolic product to be determined.  
 
Farhane et al.[72] took this a step further, using Raman spectroscopy to determine not only 
subcellular location of delivered drug, but also the effects the drug has on cellular Raman 
signature (Figure 2). This thorough study investigated the uptake of doxorubicin to A549 
human lung adenocarcinoma cells. Raman microspectroscopy confirmed fluorescence results, 
indicating that doxorubicin was localised to the nucleus after 24 hr exposure, as doxorubicin 
peaks were only observed in spectra from the nucleus and nucleolus, and not the cytoplasm. 
In addition to subcellular localisation of doxorubicin, PCA was employed to distinguish 
cellular biochemical changes in each distinct cellular region in response to drug exposure, 
and elucidate the mechanism of drug action. A further study by Farhane et al.[73] 
demonstrated that Raman spectroscopy could be employed to differentiate the respective 
responses of two different lung cancer lines (A549 and Calu I) to doxorubicin exposure, 
indicating that Raman can be employed to help understand cellular resistance pathways.  
 
Finally, Nawaz et al.[48] performed a very interesting study, applying partial least squares 
regression analysis (PLSR) to build a predictive model on the interaction of the 
chemotherapeutic agent cisplatin with lung adenocarcinoma cells. In order to build the 
predictive model they correlated Raman measurements with the standard MTT cytotoxicity 
assay, and performed Raman measurements also on isolated DNA exposed to cisplatin. 
Using this technique, they were able to distinguish cellular responses in the Raman spectrum 
as a result of cisplatin interacting with the cell by chemical binding, and the subsequent 
cellular physiological response on the cell. Therefore, detailed information on the molecular 
level interaction of the drug was gained, and the PLSR model could be used to predict 
response to application of an unknown concentration of cisplatin. This information can be 
used to build up a database correlating spectral response to drug interactions, which could be 
used as a reference point for establishing ‘mode of action’ for new drugs spectroscopically. 
Keating et al.[74] went on to confirm these results with simulated data, further emphasising 
the power of this technique, with application to HTS for in vitro drug testing. 
 
6. An alternative technique – surface enhanced Raman spectroscopy (SERS) 
 
One of the major downfalls of Raman spectroscopy is that it is an inherently weak process, 
and therefore, to obtain significant signal-to-noise, longer acquisition times tend to be 
required. Surface enhanced Raman spectroscopy (SERS), uses the plasmonic properties of 
roughened metal nanoparticles, to enhance Raman signals by up to 1015.[75] SERS has become 
a popular technique in multiple research areas including materials and electrochemistry, as 
well as in biomedical research areas.[76] SERS can be used to enhance native Raman signals, 
by close proximity to roughened metal surfaces. However, perhaps the more promising 
application is to probe for specific interactions, for example by detection of specific 
antigens[37] or enzyme activity[18,77]. Kneipp et al.[78] demonstrated the use of SERS to 
enhance Raman signals in single cells, therefore decreasing the acquisition time for a single 
map significantly. While SERS has the downfall of being an invasive technique, this could 
perhaps be compensated for in HTS by its ability to rapidly increase assay speed. In this 
manner, SERS could potentially detect the same changes as observed in spontaneous Raman 
spectra in response to drug application, with much faster acquisition times and therefore 
assay speed.  
 
Austin et al.[19] used a technique termed targeted plasmonically enhanced single cell imaging 
spectroscopy (T-PESCIS), based on enhanced SERS and Rayleigh scattering from cells treated 
with targeted nanoparticles. They observed changes in intensity of so called ‘death-bands’ in 
response to application of the chemotherapy drugs cisplatin and 5-fluorouracil (5-FU) to 
human oral squamous carcinoma cells. This allowed drug efficacy to be determined from the 
changing intensity of particular SERS bands, highlighting its potential for use in assays for 
high throughput drug screening. In this example, nanoparticles were targeted to the nuclei of 
cells. Nanoparticles have been targeted to various specific cell regions and characteristics – 
for example Von-Dinh patented a technology where nanoparticles were designed to detect 
specific cellular components, both intracellular and extracellular.[79] This was proposed as a 
platform to allow high throughput drug screening, using multiple nanoprobes. Potentially 
multiple nanoprobes could be combined in one assay to provide multiplexed detection of an 
array of cellular characteristics. Multiplexing capability is one of the major advantages of 
SERS over fluorescence based assays.[38] The sharp spectral signals in SERS compared to the 
broad fluorescence signals allow for multiple probes to be used in a single assay. In terms of 
HTS this is greatly beneficial as it provides increased information in one assay, potentially 
decreasing the need for additional assays and increasing speed. 
 
A closely related technique to SERS is surface enhanced resonance Raman scattering (SERRS) 
and this has been widely used in biological assays with potential HTS capability. SERRS 
employs a reporter ‘dye’ molecular that is attached to the nanoparticle and absorbs at 
approximately the same wavelength as the nanoparticle is resonant. Therefore even greater 
enhancement in signal is observed. In this case, the signal observed is that from the dye on 
the nanoparticle, which is turned ‘on’ or ‘off’ by the presence of, for example, a particular 
enzyme. By combining nanoparticles functionalised with different dye molecules and careful 
selection of combination, a multiplexed assay can be designed.[38] Nanoparticles have been 
functionalised with antibodies designed to detect specific antigen markers in immunoassays 
based on both SERS and SERRS techniques.[37,80–82] SERRS based assays have also been 
used to detect enzyme activity. Moore et al.[77] designed an assay to detect a variety of 
enzyme activities including from lipases, esterases and proteases. In these assays, a substrate 
consisting of a recognition site for a particular enzyme, a linker that can be cleaved by the 
particular enzyme and a SERRS-active dye was synthesised. In addition, silver nanoparticles 
were used in the assay. In the presence of the particular enzyme of interest, the substrate is 
cleaved, releasing the SERS-active dye, which then complexes to the surface of the 
nanoparticles, giving a SERS response.  This assay was developed using isolated enzymes, 
and thus gives an example of a biochemical type assay that was proposed for use in HTS, as it 
allowed enzyme concentrations commonly found in vivo to be detected. SERS has also been 
demonstrated for detection of intracellular enzyme activity. Stevenson et al.[18] reported the 
first example of detection of a specific intracellular enzyme activity using SERS. In their 
assay, activity of the enzyme β-galactosidase was detected inside cells with subcellular 
resolution. The common ELISA reagent 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside 
(X-gal) was delivered to cells along with gold nanoparticles, and a SERS response was 
observed when X-Gal was converted to the coloured product 5-5’-dimbromo-4,4’-dichloro-
indigo by β-galactosidase. The main advantages of this technique over fluorescence detection 
of enzyme activity were the ability to achieve subcellular resolution of enzyme activity and 
the multiplexing potential of the assay. It also demonstrates that, enzyme activity could be 
detected in a cellular as well as biochemical type assay, potentially for HTS technology.  
 
In addition to more direct measurement of the effect of a drug on, for example, activity of a 
specific enzyme, a study from Jaworska et al.[83] used SERS nanosensors to measure the 
intracellular pH in endothelial cells, and how this changed in response to application of 
tumour necrosis factor-α (Figure 3). Therefore, drug compounds could be screened indirectly 
by measurement of physiological characteristics, in this particular example pH, for their 
action. Nanosensors to measure intracellular pH have been reported in many studies, the 
most common being 4-mercaptobenzoic acid functionalised nanoparticles.[84–87] Auchinvole 
et al.[88] also developed nanosensors for measurement of intracellular redox potential, a key 
physiological characteristic, with changes in redox potential often associated with disease 
development. This is therefore a key characteristic that could be monitored in HTS assays to 
monitor response to drug treatment. An array of nanosensors with different small molecule 
functionalities has already been developed to measure redox potential in different 
intracellular redox environments.[89,90] Again, these SERS nanosensors have the benefit of 
multiplexing capability and have been used to measure both intracellular pH and redox 
potential simultaneously (Figure 3(e)).[91]  
 
7. Future perspectives: are nonlinear Raman techniques the answer? 
 
As mentioned, the primary downfall of Raman spectroscopy is the long acquisition times due 
to the inherently weak signals. Nonlinear Raman techniques, particularly stimulated Raman 
spectroscopy (SRS) and coherent anti-Stokes Raman spectroscopy (CARS), have emerged as 
incredibly promising methods for achieving high resolution label free information over much 
shorter acquisition times than spontaneous Raman.[92] Therefore, these nonlinear techniques 
could overcome the main disadvantage of spontaneous Raman spectroscopy and provide a 
rapid label free detection method for high throughput spectroscopic screening. CARS and 
SRS involve interrogating the sample with two laser beams of different frequency – a pump 
beam and a probe/Stokes beam.[92] Where the difference in frequency between the pump and 
Stokes beam match a vibrational energy transition, that vibrational transition is interrogated. 
CARS involves stimulating the coherent vibration of a chemical bond via the application of a 
pump and Stokes beam, which interacts with another pump photon, then leading to emission 
of an anti-Stokes photon. In SRS, when the pump and Stokes beam interrogate a sample with 
an energy difference equal to a chemical bond vibrational energy, the molecule is stimulated 
into the excited vibrational state. In this process energy is transferred from the pump to 
Stokes beam, resulting in the disappearance of the pump photon and creation of a second 
Stokes photon. The disadvantage of CARS, compared to SRS, is that, a non-resonant 
background is present in CARS measurements at the frequency of the anti-Stokes. This is not 
present in SRS.[92] 
 
Significantly, CARS and SRS, as well as spontaneous Raman, have been used to study lipids 
and lipid metabolism in vitro. This is particularly significant as lipids are difficult to study 
using other techniques – they are non fluorescent and difficult to label for fluorescence 
studies.[92] Raman techniques give strong lipid signals and therefore open up new 
opportunities for studying lipids, in particular here, how they might change in response to 
drug treatment. CARS and SRS techniques have been widely used for the study of lipid 
distribution and dynamics.[93,94] Many studies have been carried out on model organisms 
such as Caenorhabditis elegans[94,95], showing the ability of these techniques to image lipids 
with high contrast. Hellerer et al.[95] report on the study of lipid storage in Caenorhabditis 
elegans using CARS and how genetic variations affect this. There is potential for these 
techniques to be extended to study how lipid storage and metabolism is altered in response 
to drug treatment.  
 
In addition to potentially monitoring the effect of a drug on cellular biomolecules such as 
lipids, CARS and SRS have been used to image drug distribution itself, by tuning in to 
specific vibrational frequencies of drug molecules. This is an emerging area of research with 
great potential for HTS application in a label free and quick manner. Kang et al.[96] used 
CARS to visualize the distribution of the drug paclitaxel in polymer films in 3D. As a result of 
the added benefit of lack of non-resonant background in SRS compared to CARS, as well as a 
linear concentration dependence and lack of spectral distortion, SRS could perhaps provide 
the answer to high throughput spectroscopic drug screening. Tipping et al.[20] recently 
reviewed SRS as “an emerging tool for drug discovery”.  In this review, the potential for SRS 
as the latest development for in vitro drug screening is explored, pointing towards SRS as the 
future for spectroscopic HTS. In a particularly exciting study, Fu et al.[97] used hyperspectral 
SRS to study the uptake and distribution of two tyrosine-kinase inhibitors (TKI), imatinib and 
nilotinib, in murine cell line BaF3 cells. Hyperspectral SRS images a number of Raman 
frequencies, providing additional biochemical information regarding the drug distribution 
inside cells by allowing both the drug and cellular signals to be recorded. This study revealed 
lysosomal accumulation of the drugs, and allowed mechanisms behind the accumulation of 
the drugs in cells to be elucidated. Lysosomal accumulation of imatinib was decreased by 
addition of chloroquine, increasing cytosolic drug availability. Therefore, the information 
gained through hyperspectral SRS allowed detailed information on drug uptake and 
distribution to be gained, and methods to alter this were developed, with potential for 
increased efficacy. While these non-linear Raman techniques are at the early stages of 
development for potential spectroscopic HTS, they may be the solution to providing a label 
free, fast method for analysing drug uptake, distribution, metabolism, and physiological 
effects intracellularly. 
 
 
 
 
8. Conclusion: high throughput spectroscopic screening – a reality? 
 
This review has highlighted some of the key developments in the use of vibrational 
spectroscopy for analysis of drug-cell interactions. HTS is a relatively recent development in 
biomedical research and has allowed the preclinical screening of drug candidates to be 
rapidly increased in speed. HTS requires detection techniques to assess the action of potential 
drug molecules. Typically, these assays are fluorescence based and involve monitoring a 
specific phenotype or specific drug-protein binding interaction. The key characteristics of 
such a detection mechanism are: simple, cheap, fast and efficient. Here the question is posed: 
could high-throughput vibrational spectroscopic screening improve drug development. In 
order to do so it needs to meet these key characteristics and supersede the current techniques 
in doing so. In this review, a number of examples have been given of how vibrational 
spectroscopy has been used to detect cellular response to drugs, summarised in Figure 4 in 
comparison to fluorescence. In particular, FTIR and Raman techniques are considered in 
application to cell based in vitro assays. One of the major benefits of these techniques is that 
they are label free – both decreasing cost due to lack of regents required, and increasing speed 
as this removes additional assay steps involving reagents addition and detection. Another 
major benefit is the wealth of information acquired in a single vibrational spectrum. Data is 
multivariate, and therefore can reveal detailed biochemical information on the cellular 
interaction of a drug candidate. While this also increases computational power required to 
perform multivariate data analysis, it allows both simple ‘on’ or ‘off’ response to drug to be 
determined by overall analysis of biochemical changes, but can also reveal more detailed and 
specific information potentially relating to ‘mode of action’ and potential side effects. This 
could reduce the number of assays required in the overall drug screening process. In 
particular, Raman spectroscopy has shown both overall drug response in addition to 
subcellular localisation of a drug molecule and its metabolites. While IR and Raman 
spectroscopy pose major advantages for HTS, there remain potential drawbacks. In IR 
spectroscopy, large water contributions in aqueous samples and Mie scattering pose 
problems, that require microfluidic devices and computer correction algorithms to get round. 
Raman spectroscopy provides fewer problems, with perhaps the main consideration being 
the cost of substrate to minimise background signal from this. While higher cost substrates 
are favourable, it has been shown that low cost glass is adequate with careful wavelength 
selection. SERS and SERRS are introduced as additional vibrational techniques with potential 
for HTS. These techniques have already been extensively developed for immunoassay type 
screening, able to detect specific antigens. Assays have also been developed for monitoring of 
enzyme activity both in isolated enzyme assays and inside cells. While these are invasive 
techniques, negating the label free advantage of IR or spontaneous Raman screening, they 
provide many benefits including enhanced signal compared to Raman and therefore a 
decrease in acquisition time. The major benefits of these assays over their fluorescent 
counterparts are lack of photobleaching, increased subcellular resolution and ability for 
multiplexing. Finally, the non-linear Raman techniques CARS and SRS, have potential to 
overcome the speed issues of spontaneous Raman spectroscopy, providing a fast, label free 
platform for spectroscopic HTS of drug candidates to elucidate on drug uptake, distribution 
and physiological response in vitro.  
 
While Raman and IR may not surpass the present on/off throughput rates in terms of number 
of screening events in a given time, by providing a more holistic view of the biochemistry of 
the cell, and therefore, in the same screen allowing multiple characteristics to be probes such 
as toxicity, drug uptake, subcellular trafficking of drug, binding events and efficacy, the 
overall throughput could be increased by reducing the number of screening events required 
per drug candidate. By being non invasive, Raman and IR also reduce the number of steps in 
the screening process. SERS/SERRS and CARS/SRS provide a less holistic view of cellular 
biochemistry, instead often focusing on specific interactions or events. These techniques are 
faster, competing with current HTS methods. Ultimately, CARS and SRS could allow real 
time screening. Figure 5 summarises the potential workflow of high throughput vibrational 
spectroscopic screening, including reference to the various spectroscopic methods discussed 
and the reasons for selecting each. Brief reference is also made to sample preparation 
methods. As mentioned throughout the review, consideration of sample preparation is 
important for spectroscopic measurements. It is possible for all spectroscopic measurements 
to be made on both live and fixed samples although in the case of IR, fixed samples are 
particularly preferable due to the influence of water and the need for water correction 
algorithms discussed. While sample substrate can have a large affect on the quality of data 
acquired, as discussed, particularly in relation to IR and Raman techniques, HTS is 
characterised by the need for low cost. Therefore, despite background contributions, the 
substrate of choice would be glass. Due to the large enhancements, substrate is not important 
in SERS/SERRS assays and these could become the favoured method in high throughput 
spectroscopic screening. Therefore, the various spectroscopic methods discussed all have 
their merits and could be selected dependent on the screening application in question. These 
complimentary techniques highlight the additional advantage of vibrational spectroscopic 
screening by showcasing the array of ‘tools’ to select from dependent on the particular 
application in question. The spectroscopic technique employed could be selected by 
consideration of the points discussed in this article and summarised in the workflow in 
Figure 5. Perhaps, ultimately, the faster nonlinear Raman techniques of CARS and SRS, which 
could allow real time monitoring of drug action and localisation, hold the key to the 
progression of high throughput vibrational spectroscopic screening. 
 
Acknowledgements 
L. Jamieson would like to thank Caryn Hughes for her input and support.  
 
References 
[1] L.M. Almond, J. Hutchings, G. Lloyd, H. Barr, N. Shepherd, J. Day, O. Stevens, S. 
Sanders, M. Wadley, N. Stone, C. Kendall, Endoscopic Raman spectroscopy enables 
objective diagnosis of dysplasia in Barrett’s esophagus, Gastrointest. Endosc. 79 (2014) 
37–45. doi:10.1016/j.gie.2013.05.028. 
[2] D.C. Fernandez, R. Bhargava, S.M. Hewitt, I.W. Levin, Infrared spectroscopic imaging 
for histopathologic recognition., Nat. Biotechnol. 23 (2005) 469–474. 
doi:10.1038/nbt1080. 
[3] A. Khoshmanesh, M.W.A. Dixon, S. Kenny, L. Tilley, D. McNaughton, B.R. Wood, 
Detection and Quantification of Early-Stage Malaria Parasites in Laboratory Infected 
Erythrocytes by Attenuated Total Reflectance Infrared Spectroscopy and Multivariate 
Analysis., Anal. Chem. 86 (2014) 4379-4386. doi:10.1021/ac500199x. 
[4] L. Lovergne, G. Clemens, V. Untereiner, R.A. Lukaszweski, G.D. Sockalingum, M.J. 
Baker, Investigating optimum sample preparation for infrared spectroscopic serum 
diagnostics, Anal. Methods. 7 (2015) 7140-7149. doi:10.1039/C5AY00502G. 
[5] F.M. Lyng, D. Traynor, I.R.M. Ramos, F. Bonnier, H.J. Byrne, Raman spectroscopy for 
screening and diagnosis of cervical cancer, Anal. Bioanal. Chem. 407 (2015) 8279-8289. 
doi:10.1007/s00216-015-8946-1. 
[6] H.J. Byrne, M. Baranska, G.J. Puppels, N. Stone, B. Wood, K.M. Gough, P. Lasch, P. 
Heraud, J. Sulé-Suso, Spectropathology for the next generation: Quo vaids?, Analyst. 
140 (2015) 2066–2073. doi:10.1039/c4an02036g. 
[7] The International Society for Clinical Spectroscopy, http://clirspec.org (accessed April 
8, 2016). 
[8] Raman4Clinics, https://www.raman4clinics.eu (accessed May 24, 2016). 
[9] Laser detects brain tumour cells during surgery, http://www.bbc.co.uk/news/health-
34041863 (accessed September 6, 2015). 
[10] M. Jermyn, K. Mok, J. Mercier, J. Desroches, J. Pichette, K. Saint-Arnaud, L. Bernstein, 
M.-C. Guiot, K. Petrecca, F. Leblond, Intraoperative brain cancer detection with 
Raman spectroscopy in humans, Sci. Transl. Med. 7 (2015) 274ra19–274ra19. 
doi:10.1126/scitranslmed.aaa2384. 
[11] Infrared light puts malaria to the test, http://monash.edu/news/show/infrared-light-
puts-malaria-to-the-test (accessed September 6, 2015). 
[12] Legislation for the protection of animals used for scientific purposes, 
http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm (accessed 
May 15, 2016). 
[13] Public Law 106–387 106th Congress An Act, (2001). 
[14] A.A. Hajare, S.S. Salunkhe, S.S. Mali, S.S. Gorde, S.J. Nadaf, S.A. Pishawikar, Review 
on: High-throughput screening is an approach to drug discovery, Am. J. PharmTech 
Res. 4 (2013) 112–129.  
[15] C. Hughes, G. Clemens, M.J. Baker, Preclinical screening of anticancer drugs using 
infrared (IR) microspectroscopy, Trends Biotechnol. 33 (2015) 429–430. 
doi:10.1016/j.tibtech.2015.03.010. 
[16] H. Nawaz, F. Bonnier, P. Knief, O. Howe, F.M. Lyng, A.D. Meade, H.J. Byrne, 
Evaluation of the potential of Raman microspectroscopy for prediction of 
chemotherapeutic response to cisplatin in lung adenocarcinoma., Analyst. 135 (2010) 
3070-3076. doi:10.1039/c0an00541j. 
[17] A. Derenne, R. Gasper, E. Goormaghtigh, The FTIR spectrum of prostate cancer cells 
allows the classification of anticancer drugs according to their mode of action., 
Analyst. 136 (2011) 1134–1141. doi:10.1039/c0an00872a. 
[18] R. Stevenson, S. McAughtrie, L. Senior, R.J. Stokes, H. McGachy, L. Tetley, P. Nativo, 
J.M. Brewer, J. Alexander, K. Faulds, D. Graham, Analysis of intracellular enzyme 
activity by surface enhanced Raman scattering., Analyst. 138 (2013) 6331–6336. 
doi:10.1039/c3an00729d. 
[19] L.A. Austin, B. Kang, M.A. El-Sayed, A New Nanotechnology Technique for 
Determining Drug E ffi cacy Using Targeted Plasmonically Enhanced Single Cell 
Imaging Spectroscopy, J. Am. Chem. Soc. 135 (2013) 4688-4691. doi: 10.1021/ja4011145. 
[20] W.J. Tipping, M. Lee, A. Serrels, V.G. Brunton, A.N. Hulme, Stimulated Raman 
scattering microscopy: an emerging tool for drug discovery, Chem. Soc. Rev. 45 (2016) 
2075–2089. doi:10.1039/C5CS00693G. 
[21] P. Szymański, M. Markowicz, E. Mikiciuk-Olasik, Adaptation of high-throughput 
screening in drug discovery-toxicological screening tests, Int. J. Mol. Sci. 13 (2012) 427–
452. doi:10.3390/ijms13010427. 
[22] D.L. Boger, B.E. Fink, M.P. Hedrick, Total synthesis of distamycin A and 2640 
analogues: A solution-phase combinatorial approach to the discovery of new, 
bioactive DNA binding agents and development of a rapid, high-throughput screen 
for determining relative DNA binding affinity or DNA binding selectivity, J. Am. 
Chem. Soc. 122 (2000) 6382–6394. doi:10.1021/ja994192d. 
[23] I. Torjesen, Drug development: the journey of a medicine from lab to shelf, Pharm. J. 
(2015). http://www.pharmaceutical-journal.com/publications/tomorrows-
pharmacist/drug-development-the-journey-of-a-medicine-from-lab-to-
shelf/20068196.article (accessed April 8, 2016). 
[24] D. Barata, C. van Blitterswijk, P. Habibovic, High-throughput screening approaches 
and combinatorial development of biomaterials using microfluidics, Acta Biomater. 34 
(2015) 1–20. doi:10.1016/j.actbio.2015.09.009. 
[25] N. Boute, R. Jockers, T. Issad, The use of resonance energy transfer in high-throughput 
screening: BRET versus FRET, Trends Pharmacol. Sci. 23 (2002) 351–354. 
doi:10.1016/S0165-6147(02)02062-X. 
[26] D.S. Smith, S.A. Eremin, Fluorescence polarization immunoassays and related 
methods for simple, high-throughput screening of small molecules, Anal. Bioanal. 
Chem. 391 (2008) 1499–1507. doi:10.1007/s00216-008-1897-z. 
[27] Y. Jia, C.M. Quinn, A.I. Gagnon, R. Talanian, Homogeneous time-resolved 
fluorescence and its applications for kinase assays in drug discovery, Anal. Biochem. 
356 (2006) 273–281. doi:10.1016/j.ab.2006.05.006. 
[28] M. Auer, K.J. Moore, F.J. Meyer-Almes, R. Guenther, A.J. Pope, K.A. Stoeckli, 
Fluorescence correlation spectroscopy: Lead discovery by miniaturized HTS, Drug 
Discov. Today. 3 (1998) 457–465. doi:10.1016/S1359-6446(98)01240-9. 
[29] J. Inglese, R.L. Johnson, A. Simeonov, M. Xia, W. Zheng, C.P. Austin, D.S. Auld, High-
throughput screening assays for the identification of chemical probes., Nat. Chem. 
Biol. 3 (2007) 466–479. doi:10.1038/nchembio.2007.17. 
[30] A.M. Maffia III, I. Kariv, K.R. Oldenburg, Miniaturization of a Mammalian Cell-Based 
Assay: Luciferase Reporter Gene Readout in a 3 Microliter 1536-Well Plate, J. Biomol. 
Screen. 4 (1999) 137-142. doi:10.1177/108705719900400307. 
[31] L.A. Collins, M.N. Torrero, S.G. Franzblau, Green fluorescent protein reporter 
microplate assay for high-throughput screening of compounds against 
Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 42 (1998) 344–347. 
[32] M. Berg, K. Undisz, R. Thiericke, T. Moore, C. Posten, Miniaturization of an enzyme 
assay (β-galactosidase) in the 384- and 1536-well plate format, J. Assoc. Lab. Autom. 4 
(1999) 64–67. doi:10.1016/S1535-5535(04)00042-5. 
[33] Y-M. Go, D.P. Jones, Redox compartmentalization in eukaryotic cells, Biochim. 
Biophys. Acta., 1780 (2009) 1273–1290. doi:10.1016/j.bbagen.2008.01.011. 
[34] R. Hamid, Y. Rotshteyn, L. Rabadi, R. Parikh, P. Bullock, Comparison of alamar blue 
and MTT assays for high through-put screening, Toxicol. Vitr. 18 (2004) 703–710. 
doi:10.1016/j.tiv.2004.03.012. 
[35] V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity 
screening., Nat. Protoc. 1 (2006) 1112–1116. doi:10.1038/nprot.2006.179. 
[36] High Throughput Raman Spectrometer, http://www.is-instruments.com/high-
throughput-raman-spectrometer.html (accessed April 25, 2016). 
[37] R. Stevenson, A. Ingram, H. Leung, D.C. McMillan, D. Graham, Quantitative SERRS 
immunoassay for the detection of human PSA., Analyst. 134 (2009) 842–844. 
doi:10.1039/b902174d. 
[38] S. Laing, K. Gracie, K. Faulds, Multiplex in vitro detection using SERS, Chem. Soc. 
Rev. 45 (2016) 1901–1918. doi:10.1039/C5CS00644A. 
[39] H.J. Byrne, P. Knief, M.E. Keating, F. Bonnier, Spectral pre and post processing for 
infrared and Raman spectroscopy of biological tissues and cells, Chem. Soc. Rev. 45 
(2016) 1865–1878. doi:10.1039/C5CS00440C. 
[40] P. Bassan, A. Kohler, H. Martens, J. Lee, H.J. Byrne, P. Dumas, E. Gazi, M. Brown, N. 
Clarke, P. Gardner, Resonant Mie scattering (RMieS) correction of infrared spectra 
from highly scattering biological samples., Analyst. 135 (2010) 268–277. 
doi:10.1039/b921056c. 
[41] S.W. Bruun, A. Kohler, I. Adt, G.D. Sockalingum, M. Manfait, H. Martens, Correcting 
attenuated total reflection-fourier transform infrared spectra for water vapor and 
carbon dioxide, Appl. Spectrosc. 60 (2006) 1029–1039. doi:10.1366/000370206778397371. 
[42] L.T. Kerr, H. Byrne, B.M. Hennelly, Optimal choice of sample substrate and laser 
wavelength for Raman spectroscopic analysis of biological specimen, Anal. Methods. 
7 (2015) 5041–5052. doi:10.1039/C5AY00327J. 
[43] K.H. Liland, A. Kohler, N.K. Afseth, Model-based pre-processing in Raman 
spectroscopy of biological samples, J. Raman Spectrosc. (2016). doi:10.1002/jrs.4886. 
[44] M.J. Baker, C.S. Hughes, K.A. Hollywood, Biophotonics: Vibrational Spectroscopic 
Diagnostics, Morgan & Claypool Publishers, 2016. doi:10.1088/978-1-6817-4071-3. 
[45] B. Bird, M.J. Baker, Quantum Cascade Lasers in Biomedical Infrared Imaging, Trends 
Biotechnol. 33 (2015) 557–558. doi:10.1016/j.tibtech.2015.07.003. 
[46] S.F. El-Mashtoly, D. Petersen, H.K. Yosef, A. Mosig, A. Reinacher-Schick, C. Kötting, 
K. Gerwert, Label-free imaging of drug distribution and metabolism in colon cancer 
cells by Raman microscopy., Analyst. 139 (2014) 1155–1161. doi:10.1039/c3an01993d. 
[47] Z. Farhane, F. Bonnier, A. Casey, H.J. Byrne, Raman micro spectroscopy for in vitro 
drug screening: subcellular localisation and interactions of doxorubicin, Analyst. 140 
(2015) 4212–4223. doi:10.1039/c5an00256g. 
[48] H. Nawaz, F. Bonnier, P. Knief, O. Howe, F. M. Lyng, A. D. Meade, H. J. Byrne,  
Evaluation of the potential of Raman microspectroscopy for prediction of 
chemotherapeutic response to cisplatin in lung adenocarcinoma., Analyst. 135 (2010) 
3070–6. doi:10.1039/c0an00541j. 
[49] M. Miljković, T. Chernenko, M.J. Romeo, B. Bird, C. Matthäus, M. Diem, Label-free 
imaging of human cells: algorithms for image reconstruction of Raman hyperspectral 
datasets., Analyst. 135 (2010) 2002–13. doi:10.1039/c0an00042f. 
[50] M.E. Keating, F. Bonnier, H.J. Byrne, Spectral cross-correlation as a supervised 
approach for the analysis of complex Raman datasets: the case of nanoparticles in 
biological cells, Analyst. (2012) 5792–5802. doi:10.1039/c2an36169h. 
[51] P. Lasch, M. Diem, W. Hänsch, D. Naumann, Artificial neural networks as supervised 
techniques for FT-IR microspectrocopic imaging. J. Chemometrics 20 (2006) 209-220. 
doi:10.1002/cem993. 
[52] A. Gaigneaux, J.M. Ruysschaert, E. Goormaghtigh, Infrared spectroscopy as a tool for 
discrimination between sensitive and multiresistant K562 cells, Eur. J. Biochem. 269 
(2002) 1968–1973. doi:10.1046/j.1432-1327.2002.02841.x. 
[53] L.M. Miller, P. Dumas, Chemical imaging of biological tissue with synchrotron 
infrared light, Biochim. Biophys. Acta - Biomembr. 1758 (2006) 846–857. 
doi:10.1016/j.bbamem.2006.04.010. 
[54] A. Derenne, V. Van Hemelryck, D. Lamoral-Theys, R. Kiss, E. Goormaghtigh, FTIR 
spectroscopy: A new valuable tool to classify the effects of polyphenolic compounds 
on cancer cells, Biochim. Biophys. Acta - Mol. Basis Dis. 1832 (2013) 46–56. 
doi:10.1016/j.bbadis.2012.10.010. 
[55] R. Gasper, T. Mijatovic, A. Bénard, A. Derenne, R. Kiss, E. Goormaghtigh, FTIR 
spectral signature of the effect of cardiotonic steroids with antitumoral properties on a 
prostate cancer cell line, Biochim. Biophys. Acta - Mol. Basis Dis. 1802 (2010) 1087–
1094. doi:10.1016/j.bbadis.2010.07.012. 
[56] F. Nie, X.-L. Yu, X.-G. Wang, Y.-F. Tang, L.-L. Wang, L. Ma, Down-regulation of 
CacyBP is associated with poor prognosis and the effects on COX-2 expression in 
breast cancer., Int. J. Oncol. 37 (2010) 1261–1269. doi:10.3892/ijo. 
[57] G. Berger, H. Leclercqz, A. Derenne, M. Gelbcke, E. Goormaghtigh, J. Nève, V. 
Mathieu, F. Dufrasne, Synthesis and in vitro characterization of platinum(II) 
anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method 
for new compound discovery, Bioorganic Med. Chem. 22 (2014) 3527–3536. 
doi:10.1016/j.bmc.2014.04.017. 
[58] M.J. Baker, J. Trevisan, P. Bassan, R. Bhargava, H.J. Butler, K.M. Dorling, P.R. Fielden, 
S.W. Fogarty, N.J. Fullwood, K.A. Heys, C. Hughes, P. Lasch, P.L. Martin-Hirsch, B. 
Obinaju, G.D. Sockalingum, J. Sulé-Suso, R.J. Strong, M.J. Walsh, B.R. Wood, P. 
Gardner, F.L. Martin, Using Fourier transform IR spectroscopy to analyze biological 
materials., Nat. Protoc. 9 (2014) 1771–1791. doi:10.1038/nprot.2014.110. 
[59] Perkin Elmer, Technical Note, The Effects of Varying Force and Contact on ATR 
Spectra, Tech. Note. (2012) 4–6. 
[60] E. Levenson, P. Lerch, M.C. Martin, Spatial resolution limits for synchrotron-based 
spectromicroscopy in the mid- and near-infrared, J. Synchrotron Radiat. 15 (2008) 323–
328. doi:10.1107/S0909049508004524. 
[61] C. Hughes, A. Henderson, M. Kansiz, K. Dorling, M. Jimenez-Hernandez, M.D. 
Brown, N.W. Clarke, P. Gardner, Enhanced FTIR benchtop imaging of single 
biological cells, Analyst. (2015) 2080–2085. doi:10.1039/C4AN02053G. 
[62] F. Draux, P. Jeannesson, C. Gobinet, J. Sulé-Suso, J. Pijanka, C. Sandt, P. Dumas, M. 
Manfait, G.D. Sockalingum, IR spectroscopy reveals effect of non-cytotoxic doses of 
anti-tumour drug on cancer cells, Anal. Bioanal. Chem. 395 (2009) 2293–2301. 
doi:10.1007/s00216-009-3140-y. 
[63] C. Hughes, M.D. Brown, F.J. Ball, G. Monjardez, N.W. Clarke, K.R. Flower, P. 
Gardner, Highlighting a need to distinguish cell cycle signatures from cellular 
responses to chemotherapeutics in SR-FTIR spectroscopy., Analyst. 137 (2012) 5736–
5742. doi:10.1039/c2an35633c. 
[64] A. Derenne, A. Mignolet, E. Goormaghtigh, FTIR spectral signature of anticancer drug 
effects on PC-3 cancer cells: is there any influence of the cell cycle?, Analyst. 138 (2013) 
3998–4005. doi:10.1039/c3an00225j. 
[65] H-Y.N. Holman, M..C. Martin, E.A. Blakely, K. Bjornstad, W.R. McKinney, IR 
Spectroscopic Characteristics of Cell Cycle and Cell Death Probed by Synchrotron 
Radiation Based Fourier Transform IR Spectromicroscopy, Biopolymers. 57 (2000) 329-
335. doi: 10.1002/1097-0282. 
[66] M. Jimenez-Hernandez, M.D. Brown, C. Hughes, N.W. Clarke, P. Gardner, 
Characterising cytotoxic agent action as a function of the cell cycle using fourier 
transform infrared microspectroscopy., Analyst. 140 (2015) 4453–4464. 
doi:10.1039/c5an00671f. 
[67] S. Gaudenzi, D. Pozzi, P. Toro, I. Silvestri, S. Morrone, A.C. Castellano, Cell apoptosis 
specific marker found by Fourier Transform Infrared Spectroscopy, Spectroscopy. 18 
(2004) 415–422. doi:10.1155/2004/483591. 
[68] K-Z. Lui, J. Li, S.M. Kelsey, H.H. Mantsch, Quantitative determination of apoptosis on 
leukaemia cells by infrared spectroscopy., Apoptosis. 6 (2001) 267–276. 
doi:10.1023/A:1011383408381. 
[69] A. V. Rutter, M.R. Siddique, J. Filik, C. Sandt, P. Dumas, G. Cinque, G.D. Sockalingum, 
Y. Yang, J. Sulé-Suso, Study of gemcitabine-sensitive/resistant cancer cells by cell 
cloning and synchrotron FTIR microspectroscopy, Cytom. Part A. 85 (2014) 688–697. 
doi:10.1002/cyto.a.22488. 
[70] F. Bonnier, S.M. Ali, P. Knief, H. Lambkin, K. Flynn, V. McDonagh, C. Healy, T.C. Lee, 
F.M. Lyng, H.J. Byrne, Analysis of human skin tissue by Raman microspectroscopy: 
Dealing with the background, Vib. Spectrosc. 61 (2012) 124–132. 
doi:10.1016/j.vibspec.2012.03.009. 
[71] R. Buckmaster, F. Asphahani, M. Thein, J. Xu, M. Zhang, Detection of drug-induced 
cellular changes using confocal Raman spectroscopy on patterned single-cell 
biosensors., Analyst. 134 (2009) 1440–1446. doi:10.1039/b900420c. 
[72] Z. Farhane, F. Bonnier, A. Casey, H. Byrne, Raman micro spectroscopy for in vitro 
drug screening: subcellular localisation and interactions of Doxorubicin, Analyst. 
(2015) 4212–4223. doi:10.1039/C5AN00256G. 
[73] Z. Farhane, F. Bonnier, B. Marcus Alexander, Maher Jane, C. Alan, H.J. Byrne, 
Differentiating responses of lung cancer cell lines to Doxorubicin exposure: in vitro 
Raman micro spectroscopy, oxidative stress and bcl-2 protein expression, J. 
Biophotonics. (2016) 1-15. doi:10.1002/jbio.201600019. 
[74] M.E. Keating, H. Nawaz, F. Bonnier, H.J. Byrne, Multivariate statistical methodologies 
applied in biomedical Raman spectroscopy: assessing the validity of partial least 
squares regression using simulated model datasets, Analyst. 140 (2015) 2482–2492. 
doi:10.1039/c4an02167c. 
[75] E.C. Le Ru, P.G. Etchegoin, Principles of Surface-Enhanced Raman Spectroscopy, 
Chapter 4 SERS enhancement factors and related topics, Elsevier (2009). 
doi:10.1016/B978-0-444-52779-0.00009-X. 
[76] Z.Q. Tian, Surface-enhanced Raman spectroscopy: Advancements and applications, J. 
Raman Spectrosc. 36 (2005) 466–470. doi:10.1002/jrs.1378. 
[77] B.D. Moore, L. Stevenson, A. Watt, S. Flitsch, N.J. Turner, C. Cassidy, D. Graham, 
Rapid and ultra-sensitive determination of enzyme activities using surface-enhanced 
resonance Raman scattering., Nat. Biotechnol. 22 (2004) 1133–1138. 
doi:10.1038/nbt1003. 
[78] K. Kneipp, A.S. Haka, H. Kneipp, K. Badizadegan, N. Yoshizawa, C. Boone, K.E. 
Shafer-Peltier, J.T. Motz, R.R. Dasari, M.S. Feld, Surface-enhanced raman spectroscopy 
in single living cells using gold nanoparticles, Appl. Spectrosc. 56 (2002) 150–154. 
doi:10.1366/0003702021954557. 
[79] T. Vo-Dinh, Nanoprobe for surface-enhanced Raman spectroscopy in medical 
diagnostic and drug screening, 2001, US 6,219,137 B1, filed 3rd Dec 1998, issued 17th 
April 2001. 
[80] D.S. Grubisha, R.J. Lipert, H.Y. Park, J. Driskell, M.D. Porter, Femtomolar Detection of 
Prostate-Specific Antigen: An Immunoassay Based on Surface-Enhanced Raman 
Scattering and Immunogold Labels, Anal. Chem. 75 (2003) 5936–5943. 
doi:10.1021/ac034356f. 
[81] J. Ni, R.J. Lipert, G.B. Dawson, M.D. Porter, Immunoassay Readout Method Using 
Extrinsic Raman Labels Adsorbed on Immunogokld Collids, Anal. Chem. 71 (1999) 
4903–4908. doi:10.1021/ac990616a. 
[82] X.X. Han, B. Zhao, Y. Ozaki, Surface-enhanced Raman scattering for protein detection, 
Anal. Bioanal. Chem. 394 (2009) 1719–1727. doi:10.1007/s00216-009-2702-3. 
[83] A. Jaworska, L.E. Jamieson, K. Malek, C.J. Campbell, J. Choo, S. Chlopicki, M. 
Baranska, SERS-based monitoring of the intracellular pH in endothelial cells: the 
influence of the extracellular environment and tumour necrosis factor-α, Analyst. 140 
(2015) 2321-2329. doi:10.1039/c4an01988a. 
[84] S.W. Bishnoi, C.J. Rozell, C.S. Levin, M.K. Gheith, B.R. Johnson, D.H. Johnson, N.J. 
Halas, All-optical nanoscale pH meter., Nano Lett. 6 (2006) 1687–1692. 
doi:10.1021/nl060865w. 
[85] M.A. Ochsenkuehn, P.R.T. Jess, H. Stoquert, K. Dholakia, C.J. Campbell, Nanoshells 
for Surface-Enhanced Raman, ACS Nano. 3 (2009) 3613–3621. doi:10.1021/nn900681c. 
[86] J. Kneipp, H. Kneipp, B. Wittig, K. Kneipp, Following the Dynamics of pH in 
Endosomes of Live Cells with SERS Nanosensors, J. Phys. Chem. C. 114 (2010) 7421–
7426. doi:10.1021/jp910034z. 
[87] J. Kneipp, H. Kneipp, B. Wittig, K. Kneipp, One- and Two-Photon Excited Optical pH 
Probing for Cells Using Surface-Enhanced Raman and Hyper-Raman Nanosensors, 
Nano Lett. 7 (2007) 2819-2823. doi:10.1021/nl071418z. 
[88] C.A.R. Auchinvole, P. Richardson, C. McGuinnes, V. Mallikarjun, K. Donaldson, H. 
McNab, C.J. Campbell, Monitoring intracellular redox potential changes using SERS 
nanosensors., ACS Nano. 6 (2012) 888–896. doi:10.1021/nn204397q. 
[89] J. Jiang, C. Auchinvole, K. Fisher, C.J. Campbell, Quantitative measurement of redox 
potential in hypoxic cells using SERS nanosensors., Nanoscale. 6 (2014) 12104–12110. 
doi:10.1039/c4nr01263a. 
[90] P.I.T. Thomson, V.L. Camus, Y. Hu, C.J. Campbell, Series of Quinone-Containing 
Nanosensors for Biologically Relevant Redox Potential Determination by Surface-
Enhanced Raman Spectroscopy, Anal. Chem. 87 (2015) 4719-4725. 
doi:10.1021/ac504795s. 
[91] L.E. Jamieson, A. Jaworska, J. Jiang, M. Baranska, D.J. Harrison, C.J. Campbell, 
Simultaneous intracellular redox potential and pH measurements in live cells using 
SERS nanosensors, Analyst. 140 (2015) 2330-2335. doi:10.1039/c4an02365j. 
[92] A. Folick, W. Min, M.C. Wang, Label-free imaging of lipid dynamics using Coherent 
Anti-stokes Raman Scattering (CARS) and Stimulated Raman Scattering (SRS) 
microscopy, Curr. Opin. Genet. Dev. 21 (2011) 585–590. doi:10.1016/j.gde.2011.09.003. 
[93] J.P. Pezacki, J.A. Blake, D.C. Danielson, D.C. Kennedy, R.K. Lyn, R. Singaravelu, 
Chemical contrast for imaging living systems: molecular vibrations drive CARS 
microscopy, Nat. Chem. Biol. 7 (2011) 137–145. doi:10.1038/nchembio.525. 
[94] C.W. Freudiger, W. Min, G.R. Holtom, B. Xu, M. Dantus, X. Sunney Xie, X.S. Xie, 
Highly specific label-free molecular imaging with spectrally tailored excitation-
stimulated Raman scattering (STE-SRS) microscopy, Nat. Photonics. 5 (2011) 103–109. 
doi:10.1038/nphoton.2010.294. 
[95] T. Hellerer, C. Axäng, C. Brackmann, P. Hillertz, M. Pilon, A. Enejder, Monitoring of 
lipid storage in Caenorhabditis elegans using coherent anti-Stokes Raman scattering 
(CARS) microscopy., Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14658–14663. 
doi:10.1073/pnas.0703594104. 
[96] E. Kang, H. Wang, I.K. Kwon, J. Robinson, K. Park, J. Cheng, In Situ Visualization of 
Paclitaxel Distribution and Release by Coherent Anti-Stokes Raman Scattering 
Microscopy In Situ Visualization of Paclitaxel Distribution and Release by Coherent 
Anti-Stokes Raman Scattering Microscopy, Anal. Chem. 78 (2006) 8036–8043. 
doi:10.1021/ac061218s. 
[97] D. Fu, J. Zhou, W.S. Zhu, P.W. Manley, Y.K. Wang, T. Hood, A. Wylie, X.S. Xie, 
Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with 
quantitative hyperspectral stimulated Raman scattering., Nat. Chem. 6 (2014) 614–622. 
doi:10.1038/nchem.1961. 
 
  
Figure 1 FTIR spectroscopy for monitoring drug-cell interaction: Comparison between 
fluorescence for distinguishing cell cycle stage in Caki-2 cells and response to cytotoxic drugs 
5-fluorouracil (5FU) and Paclitaxel. (a) Fluorescence on Caki-2 cells stained with DAPI 
(blue/cyan), cdt1-FITC (green), germinin-TRITC (yellow) and EdU-HcRed (red), with cell cycle 
stage labeled. (b) Caki-2 cells stained with activated caspase-3 (green) and DAPI (blue) and 
untreated (top), treated with 5FU (middle) and treated with Paclitaxel (bottom). (c) A selected 
region of the second derivative spectra of Caki-2 cells control (red), treated with 5FU (green) 
and treated with Paclitaxel (blue) at different cell cycle stages labeled. (d) PLS regression 
score plot for Caki-2 cells in G1 phase treated with 5FU (pink) and Paclitaxel (black) (left) and 
centroids of the populations from 5FU, Paclitaxel and control projection (blue). (4) PLS 
regression score plot for Caki-2 cells in S phase treated with 5FU (pink) and Paclitaxel (black) 
(left) and centroids of the populations from 5FU, Paclitaxel and control projection (green). (d) 
PLS regression score plot for Caki-2 cells in G2M phase treated with 5FU (pink) and 
Paclitaxel (black) (left) and centroids of the populations from 5FU, Paclitaxel and control 
projection (red). (g) FTIR spectroscopy has been used to distinguish cell cycle stage and 
response to cytotoxic drug action discriminated between each stage. (Adapted from Jimenez-
Hernandez et al.[66] with permission from the Royal Society of Chemistry.) 
 
 
  
Figure 2 Raman spectroscopy for monitoring drug-cell interaction: Comparing 
fluorescence for imaging subcellular localization of cytotoxic drug doxorubicin and Raman 
spectroscopy to distinguish cellular response with subcellular distinction. (a) Confocal 
fluorescence image of A549 lung cancer cells control. (b) Confocal fluorescence image of 
A549 lung cancer cells treated with doxorubicin. (c) Mean Raman spectra of A549 cell 
nucleolus (green = control, black = doxorubicin treated). (d) Mean Raman spectra of A549 
cell nucleus (red = control, magenta = doxorubicin treated). (e) Mean Raman spectra of A549 
cell cytoplasm (blue = control, cyan = doxorubicin treated). (f) PCA plot of Raman spectra 
from A549 cell nuclei (red = untreated, yellow = doxorubicin treated), nucleolus (green = 
untreated, black = doxorubicin treated), and cytoplasm (blue = untreated, pink = doxorubicin 
treated). (g) Raman spectroscopy has been used to distinguish subcellular organelles and 
discriminated response to cytotoxic drug action. (Adapted from Farhane et al.[72] with 
permission from the Royal Society of Chemistry. Note non-IUPAC format of x-axis used in 
order to maintain consistency with how material originally appeared in publication.) 
 
  
Figure 3 SERS for measuring intracellular redox potential and pH and changes in 
response to drug treatment (a) SERS spectrum of mercaptobenzoic acid functionalised 
gold nanoparticles (MBA-NP) at pH 1 (black) and pH 12 (red) showing the changing 
intensities of the pH sensitive signals at ca. 1400 cm
–1
 and ca. 1700 cm
–1
. (b) EA.hy926 cells 
incubated with MBA-NPs and mapped on Raman spectrometer to locate SERS signals from 
MBA-NPs inside cells, with false colour map created using cluster analysis to assign pH 
values as indicated in key. (c) and (d) Ea.hy926 cells incubated with MBA-NPs and treated 
with tumour necrosis factor-α, followed by mapping on Raman spectrometer to locate SERS 
signals from MBA-NPs inside cells, with false colour map created using cluster analysis to 
assign pH values as indicated in key. (e) EA.hy926 cells incubated with MBA-NPs (for pH 
measurement) and AQ-NPs (for redox potential measurement), and mapped on Raman 
spectrometer to locate SERS signals from MBA-NPs and AQ-NPs inside cells, with false 
colour map created using cluster analysis to assign pH and redox potential values as 
indicated in the key. (f) SERS has been used to measure intracellular pH and its response to 
drug treatement. (Adapted from Jaworska et al.[83] and Jamieson et al.[91] with permission 
from the Royal Society of Chemistry. Note non-IUPAC format of x-axis used in order to 
maintain consistency with how material originally appeared in publication.) 
 
 
  
Figure 4 High throughput vibrational spectroscopic screening Vibrational spectroscopic 
techniques have significant potential to shape the field of HTS and provide great advantages 
over current fluorescent based assay techniques. Some of the advantages and 
disadvantages of fluorescence, FTIR spectroscopy, Raman spectroscopy, SERS and 
CARS/SRS as detection methods for HTS are highlighted.  
 
 
  
Figure 5 High throughput vibrational spectroscopic screening workflow A step by step 
guide to high throughput vibrational spectroscopic screening from sample preparation to 
screening type and the factors to consider when selecting the vibrational spectroscopic 
method selected for screening, including pre- and post- processing data analysis steps.  
 
 
